General Information of Drug (ID: DMZ6Y0T)

Drug Name
LEO-32731 Drug Info
Synonyms LP0058
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Phase 2 [1]
Psoriasis vulgaris EA90 Phase 1 [2]
Cross-matching ID
PubChem CID
54765967
CAS Number
CAS 1353546-86-7
TTD Drug ID
DMZ6Y0T

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Phosphodiesterase 4 (PDE4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [3]
Oxtriphylline DMLHSE3 Cough MD12 Approved [4]
Roflumilast DMPGHY8 Asthma CA23 Approved [5]
Ibudilast DM4LSPN Castleman's disease 4B2Y Approved [6]
crisaborole DMNVKU6 Atopic dermatitis EA80 Approved [7]
Arofylline DM84AD1 Chronic obstructive pulmonary disease CA22 Phase 3 [8]
ARQ-151 DML61S4 Atopic dermatitis EA80 Phase 3 [9]
SUN13834 DMPK34E Gram-positive bacterial infection 1B74-1G40 Phase 2 [10]
ONO-6126 DMRT28X Chronic obstructive pulmonary disease CA22 Phase 2 [8]
E6005 DM1S489 Atopic dermatitis EA80 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 4 (PDE4) TTV5CGO NOUNIPROTAC Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01310049) LEO 32731 - A Study in Healthy Male Subjects. U.S. National Institutes of Health.
3 Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
6 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
7 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
8 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
9 Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.
10 Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
11 Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.